罕见病药物氨己烯酸片多少钱一盒
As early as August 2009, it was approved by the US FDA for marketing. It is suitable for monotherapy in children aged 1 month to 2 years old. Its potential benefits for infantile spasms outweigh the potential risk of vision loss, and it can be used as an auxiliary (additional) treatment (CPS) for adult patients with refractory complex partial epilepsy. On January 16, 2019, the FDA approved the launch of a generic version of vigabatrin.
The main component of vigabatrin tablets is vigabatrin (vigabatrin). Its mechanism of action is to irreversibly inhibit GABA aminotransferase (GABA-T) and increase the concentration of GABA in the brain. In the past two years, more and more children with TSC have effectively controlled epilepsy by using vigabatrin tablets. Western countries even use vigabatrin tablets to prevent brain abnormalities in children with TSC who have not yet developed the disease. It can be seen that the effect is quite significant.
In addition to the therapeutic effect, the price of vigabatrin tablets is also of great concern to everyone. How much does a box of vigabatrin tablets cost?
It is understood that the specifications of vigabatrin tablets produced by France's Sanofi are 500mg*100 tablets, and the price is around 1,500$. The price may change due to factors such as exchange rates. For details, please consult the Medical Companion Travel Service.
In March 2019, a drug independently developed by Yuanda Pharmaceutical for the treatment of refractory partial epilepsy and infantile spasms was planned to be included in the priority review list because it complied with the provisions of the former State Food and Drug Administration's "Opinions of the General Administration on Encouraging Drug Innovation to Implement Priority Review and Approval". Vigabatrin is the only one selected as the first rare disease drug of this kind in China. It is believed that vigabatrin tablets will also be approved for marketing in my country in the near future.
Recommended related hot articles: /newsDetail/83093.html
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)